KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medpace Holdings (MEDP) Cost of Revenue: 2015-2025

Historic Cost of Revenue for Medpace Holdings (MEDP) over the last 10 years, with Sep 2025 value amounting to $463.0 million.

  • Medpace Holdings' Cost of Revenue rose 27.08% to $463.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 11.58%. This contributed to the annual value of $1.5 billion for FY2024, which is 6.71% up from last year.
  • According to the latest figures from Q3 2025, Medpace Holdings' Cost of Revenue is $463.0 million, which was up 9.37% from $423.3 million recorded in Q2 2025.
  • Medpace Holdings' 5-year Cost of Revenue high stood at $463.0 million for Q3 2025, and its period low was $181.5 million during Q1 2021.
  • Moreover, its 3-year median value for Cost of Revenue was $361.6 million (2023), whereas its average is $371.0 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first surged by 37.26% in 2021, then dropped by 0.92% in 2024.
  • Quarterly analysis of 5 years shows Medpace Holdings' Cost of Revenue stood at $220.6 million in 2021, then grew by 26.20% to $278.4 million in 2022, then climbed by 29.90% to $361.6 million in 2023, then fell by 0.92% to $358.3 million in 2024, then climbed by 27.08% to $463.0 million in 2025.
  • Its last three reported values are $463.0 million in Q3 2025, $423.3 million for Q2 2025, and $380.2 million during Q1 2025.